An observational study to evaluate caregiver's preference and treatment outcome in patient with alzheimer's disease treated with oral or tramsdermal monotheraby - Real-World Evaluation of compliance and preference in the treatment of Alzheimer's disease(RECAP).

drug protocol number
CENA713D-MAX-SA-01
drug sponsor
Novartis
drug study
Rivastigmine
drug trial site
Dr. Soliman Fakeeh Hospital (Jeddah)
drug status
Ongoing
drug phase